These new tracers have been shown in post-mortem studies to bind to AD-associated tau [21–23], and to correlate with AD dementia severity and symptoms, in contrast to Aβ [13, 16] (Fig. 3). The gene discussed is MAPT; the disease is Alzheimer disease.